Products

What will AGI do for Belimumab?

This classification denotes a monoclonal antibody with the molecular formula C6714H10428O2102S52, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73B0K5S26A, more generally known as belimumab. European Medicines Agency schedules belimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25607. The term BELIMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, list 51. Most nations, for tariff and trade purposes, schedule Belimumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BELIMUMAB remains US FDA's Preferred Term for this commodity. . Belimumab bears US NLM identifiers UMLS ID C1723401 and NCI Concept Code C91385.

How AGI delivers it

Four ways AGI delivers for Belimumab

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Belimumab, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Belimumab, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Belimumab connects

measured by

  • Aggregate Contentmodel
  • Assay Puritymodel
  • Bacterial Endotoxin Contentmodel
  • Bioactivitymodel
  • Bioassay Potencymodel
  • Chromatographic Assay Puritymodel
  • Glycosylation Profilemodel
  • Protein Concentrationmodel